Brief: Amniotics Gets Orphan Designation For Pulmostem® From The European Commission
14/12/2023 10:23
Dec 14 (Reuters) - Amniotics AB (publ) AMNI.ST :
* AMNIOTICS RECEIVES ORPHAN DESIGNATION FOR PULMOSTEM® FROM
THE
EUROPEAN COMMISSION FOR THE TREATMENT OF PRIMARY GRAFT
DYSFUNCTION FOLLOWING LUNG TRANSPLANTATION
* EXPECTS TO START A CLINICAL STUDY EVALUATING PULMOSTEM IN
THIS
INDICATION DURING 2024
Source text for Eikon: ID:nMFN3PN4Bz
Further company coverage: AMNI.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Amniotics AB (publ)
See all newsBrief: Swedish Companies Registration Office Authorises Magle Group, Amniotics Merger Plan
Brief: Amniotics H1 Net Revenue SEK 2.5 Million
Brief: Amniotics Gets Conditional Approval To Delist From Nasdaq First North Growth Market
Brief: Amniotics To Delist From Nasdaq First North Growth Market Upon Magle Group Merger Completion
Brief: Magle Chemoswed, Amniotics Adopt Merger Plan